World Trade Center Responders at Risk for Early Onset Dementia
People who sifted through piles of debris are nine times likelier to develop early onset, all-cause dementia than those exposed to little toxic dust.
6471 RESULTS
Sort By:
People who sifted through piles of debris are nine times likelier to develop early onset, all-cause dementia than those exposed to little toxic dust.
Injected into the cerebrospinal fluid, a viral vector delivers the lysosomal protein into the human brain. In mice, a protein transport vehicle delivered into the blood does the same.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
Autopsy data confirm that current tau PET tracers are unsuitable for some primary tauopathies. CryoEM structures help researchers find new ligands for tau and α-synuclein.
At SfN 2016, researchers debuted new mouse models that may better represent human disease.
Ratio of 3R/4R tau in extracellular vesicles identified people with behavioral variant FTD and PSP. Vesicle TDP43 identified bvFTD and ALS.
The huge collaborative effort unearthed 42 new risk loci and confirmed 33 others. The hits reinforce known disease pathways and predict progression.
The antibody becomes the second amyloid immunotherapy to receive traditional FDA approval, joining Leqembi.
In postmortem analyses of athletes who had repetitive head injuries, neurofibrillary tangles were more common than α-synuclein fibrils in the substantia nigra.
Preclinical studies and early phase trials target microglial receptors CD33 and TREM2, and amyloid-stoking ASC specks.
For a diagnostic test, specificity and sensitivity fall a little shy. Using two cut points might solve the problem.
Certain blood biomarker tests can tell that amyloid has built up in a person's brain and that their thinking will decline. What are the challenges ahead before these tests can be rolled out to medical care settings everywhere?
Clearance triggers improvement in downstream markers of inflammation and neurodegeneration—but not in those who started with high tangle burden. (Clue: women.)
On gantenerumab, some people with dominantly inherited AD mutations remain plaque- and tangle-free, and cognitively healthy, years after their expected age of onset.
Plasma p-tau217/tau217, alone or with Aβ42/40, identified people with amyloid pathology more accurately than did expert clinical assessment.